RxDoctor Payments DataLook up a doctor →

Scott Kellie, MD

Pulmonary Disease · Louisville, KYNPI 1235352147

Payments from drug & device makers

$14,508in general payments, 2019–2025

Across 579 payments — averaging $25.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • Boehringer Ingelheim$1K
  • GSK$1K
  • Pfizer$898
  • AstraZeneca$639
  • Actelion Pharmaceuticals US, Inc.$526
  • plus $6K from 46 others

What the payments were for

  • Travel & lodging$1,41110%
  • Food & beverage$10,00469%
  • Education$3,09221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,508 in reported general payments places this provider in the 80th percentile of 226 pulmonary disease providers in Kentucky.

See all pulmonary disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$233,548
Medicare patients
767
Services billed
3,151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter496$490,848
OfevNintedanib Esylate32$416,968
Dupixent PenDupilumab59$225,455
Breztri AerosphereBudesonide/Glycopyr/Formoterol211$170,176
Stiolto RespimatTiotropium Br/Olodaterol Hcl116$75,968
XolairOmalizumab17$68,140
Pirfenidone55$61,903
Spiriva RespimatTiotropium Bromide76$54,530
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr54$34,048
SymbicortBudesonide/Formoterol Fumarate105$33,835
Breo ElliptaFluticasone/Vilanterol55$29,893
DuleraMometasone/Formoterol29$17,598
EliquisApixaban19$14,411
Incruse ElliptaUmeclidinium Bromide25$10,560
Advair HfaFluticasone Propion/Salmeterol21$10,001

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$1,126$565,349630 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$1,143$547,465224 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$639$210,075331 claims
MerckDulera$226$17,59829 claims
PfizerEliquis$898$14,41119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 226 pulmonary disease providers in Kentucky.

Other pulmonary disease in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →